FDA permits more expansive communication between drugmakers, payers

Hoping to pave the way for greater adoption of value-based contracts, the Food and Drug Administration on Tuesday published final guidance that clarifies how drugmakers can share product information with payers while remaining compliant with FDA rules on communication.